XML 23 R10.htm IDEA: XBRL DOCUMENT v3.25.1
Liquidity and Uncertainties
3 Months Ended
Mar. 31, 2025
Liquidity and Uncertainties [Abstract]  
Liquidity and Uncertainties

Note 4 Liquidity and Uncertainties

 

The Company has recognized operating losses and net losses on a year-to-date basis in 2025 and for the years ended December 31, 2024 and 2023. Although losses have been recognized, the Company recognized positive operating cash flows for the years ended December 31, 2024 and 2023. Operating results and cash flows fluctuate based on seasonality with the first quarter typically a slower period in our calendar year. Working capital as of March 31, 2025 is $2.1 million. The Company currently believes that it will have sufficient working capital to operate for a period of at least one year from the issuance date of the March 31, 2025 interim consolidated financial statements based on future expected results.

 

The Company primarily funds operations through cash provided from operations and available capacity under our ABL Facility (“Revolver”). In 2024 the Company was not in compliance with certain of the Revolver’s financial covenants which have been waived by our lender. As of March 31, 2025, the Company was not in compliance with the Revolver’s financial covenant which has not been waived as of issuance date of these interim consolidated financial statements. In April 2025, the Company executed an amendment to the Revolver that extended the maturity date from April 2025 through June 2025. The Company and the lender are working on a longer-term extension to the Revolver and future financial covenants that the Company anticipates executing in June 2025. The Company believes the Revolver will continue to be available and the longer-term extension will be executed with financial covenants aligned to the Company’s anticipated future results.

 

Forecasted future results, the longer-term extension of the Revolver and future compliance with financial covenants are subject to risks and uncertainties which could have a material adverse effect on our business, financial condition and results of operations.

 

As more fully described in Item 5 of this Quarterly Report, on May 14, 2025, the Company entered into a common stock purchase agreement and a registration rights agreement with an accredited investor (the “Equity Line Investor”). Under the terms and subject to the conditions set forth in the Purchase Agreement, the Company has the right, but not the obligation, to sell to the Equity Line Investor, and the Equity Line Investor is obligated to purchase, up to the lesser of (a) $20,000,000 in aggregate gross purchase price of the Company’s common stock (the “Equity Line Securities”) and (b) the Exchange Cap (as defined in the Purchase Agreement).